KI Webinar Review – How Danaher’s Acquisition of Cepheid Could Shape the Molecular POC Market

KI Webinar Review – How Danaher’s Acquisition of Cepheid Could Shape the Molecular POC Market

Kalorama Information received several questions following its recent webinar regarding the molecular point-of-care (POC) in vitro diagnostics market segment and impact of recent industry M&A activity, especially Danaher’s acquisition of Cepheid. Due to the volume of questions and the time constraint of the webinar’s Q&A session, we were unable to provide live answers to all questions. This blog post addresses several related questions from the webinar and elaborates on another recent post regarding Danaher and Cepheid.


Competition Heats Up as Growth Cools in Test Services

Competition Heats Up as Growth Cools in Test Services

Growth is slower in the US, but the test service model still makes a lot of a sense for a slew of competitors with complex test products.


Join Kalorama Information on September 22 for Our Live Webinar “State of the IVD Market in 2016”

Join Kalorama Information on September 22 for Our Live Webinar “State of the IVD Market in 2016”

Kalorama Information publisher Bruce Carlson and IVD market analyst Emil Salazar will host the webinar at 2pm EST on September 22. Interested listeners should register for the event using the link provided in this post.


Cepheid is Danaher’s Key to Unlocking New Markets in Molecular Diagnostics

Cepheid is Danaher’s Key to Unlocking New Markets in Molecular Diagnostics

Kalorama Information offers market research reports relevant to this industry merger with The Market and Potential for Molecular Point of Care Diagnostics and The World Market for Cancer Diagnostics.

For an in vitro diagnostics (IVD) heavyweight, Danaher Corporation had uneven exposure to the molecular diagnostics market, one of the most dynamic and highest growing IVD market segments. Danaher’s recently announced near $4 billion acquisition of molecular diagnostics leader Cepheid effectively closes the gap in diagnostic coverage and introduces the conglomerate to key markets such as...